| Sumario: | The article focuses on the role of contract development and manufacturing organizations (CDMOs) in patient-centric drug development, particularly in the context of formulating drugs for rare diseases and cancer treatments. It highlights how patient-centric methodologies have transformed CDMO operations, emphasizing the importance of tailored pharmaceutical solutions that enhance patient adherence and convenience. The article discusses the increasing complexity of drug formulations, driven by advanced modalities like peptides and RNA therapies, which has led to greater outsourcing to CDMOs for their specialized expertise. Additionally, it notes that CDMOs are becoming strategic partners in the drug development process, providing integrated solutions that ensure regulatory compliance and optimize manufacturing processes. The anticipated growth in the outsourcing of formulation services is linked to advancements in biotechnology and the adoption of AI and automation technologies.
|
|---|